Humanin vs Noopept
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Humanin
Humanin is a mitochondrial-derived peptide with potent cytoprotective effects. Discovered in 2001, it has shown promise in protecting against age-related diseases including Alzheimer's, cardiovascular disease, and diabetes.
Full details →Noopept
Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a peptide-derived nootropic developed in Russia. While technically a dipeptide prodrug rather than a true peptide, it's often discussed alongside peptide nootropics.
Full details →Side-by-Side Comparison
| Aspect | Humanin | Noopept |
|---|---|---|
| Mechanism | Binds to IGFBP-3 and BAX, inhibiting apoptosis. Activates STAT3 signaling and enhances cellular survival under stress. Protects mitochondrial function and reduces oxidative stress. | Metabolized to cycloprolylglycine which modulates AMPA and NMDA receptors, increases NGF and BDNF expression, and provides neuroprotective effects through antioxidant mechanisms. |
| Typical Dosage | Research protocols vary widely. Studies have used doses from micrograms to milligrams depending on the analog and route. HNG (S14G-Humanin) is a more potent analog. | Oral: 10-30mg daily, typically divided into 2-3 doses. Sublingual use may enhance absorption. Some users go higher but effects may plateau. |
| Administration | Subcutaneous or intraperitoneal injection in research. Various analogs exist with different potencies and stabilities. | Oral or sublingual administration. Unlike most peptides, it's orally bioavailable. Can be taken with or without food. |
| Side Effects | Limited human data. Generally well-tolerated in animal studies. May affect glucose metabolism. | Headache (often from choline depletion), irritability, insomnia if taken late, and occasional brain fog during initial use. |
| Best For |
What They Have in Common
Both Humanin and Noopept are commonly used for: